KOREA WHO
-
-
-
CEO of D&D Pharmatech
Lee Seul-ki
Johns Hopkins Professor-Turned Founder Leads New Drug Development with Oral Peptide Platform
-
Last Updated on Apr 17, 2025
-
CEO of D&D Pharmatech
Life Summary
Lee Seul-ki is the CEO of D&D Pharmatech.
He is focused on developing highly effective and low-side-effect therapeutics based on the oral peptide platform technology ORALINK and long-acting PEGylation technology.
He was born on July 17, 1977.
He graduated from the Department of Polymer Engineering at Sungkyunkwan University and earned both his master’s and doctoral degrees in Materials Science and Engineering from GIST (Gwangju Institute of Science and Technology).
He completed postdoctoral training in biomedical engineering, radiological medicine, and theranostic nanomedicine at the Korea Institute of Science and Technology (KIST), Stanford University School of Medicine in the United States, and the U.S. National Institutes of Health (NIH).
He was a professor in the Department of Radiology at the Johns Hopkins University School of Medicine in the United States before founding D&D Pharmatech in 2014 with his father, Lee Kang-taek, a former professor at the College of Pharmacy at Sungkyunkwan University. He became CEO in 2023.
Even after becoming CEO, he continues to lead research and development. He is regarded as one of the top domestic experts in the emerging peptide field.
#LeeSeulki #DDPharmatech #ORALINK #PEGylation #peptidetherapeutics #Koreanbiotech #JohnsHopkins #StanfordNIH #biomedicalresearch #CEOscientist
He is focused on developing highly effective and low-side-effect therapeutics based on the oral peptide platform technology ORALINK and long-acting PEGylation technology.
He was born on July 17, 1977.
He graduated from the Department of Polymer Engineering at Sungkyunkwan University and earned both his master’s and doctoral degrees in Materials Science and Engineering from GIST (Gwangju Institute of Science and Technology).
He completed postdoctoral training in biomedical engineering, radiological medicine, and theranostic nanomedicine at the Korea Institute of Science and Technology (KIST), Stanford University School of Medicine in the United States, and the U.S. National Institutes of Health (NIH).
He was a professor in the Department of Radiology at the Johns Hopkins University School of Medicine in the United States before founding D&D Pharmatech in 2014 with his father, Lee Kang-taek, a former professor at the College of Pharmacy at Sungkyunkwan University. He became CEO in 2023.
Even after becoming CEO, he continues to lead research and development. He is regarded as one of the top domestic experts in the emerging peptide field.
#LeeSeulki #DDPharmatech #ORALINK #PEGylation #peptidetherapeutics #Koreanbiotech #JohnsHopkins #StanfordNIH #biomedicalresearch #CEOscientist